HOME >> BIOLOGY >> NEWS
NIEHS allocates $74 million to study environmental causes of disease

As part of the new Exposure Biology Program, the National Institute of Environmental Health Sciences, a component of the National Institutes of Health, today announced $74 million in grant opportunities for the development of new technologies that will improve the measurement of environmental exposures that contribute to human disease.

The three grant opportunities will support research to develop portable, easy-to-use sensing devices that will accurately measure personal exposure to a wide variety of chemical and biological agents. The grants will also support the development of sensitive biomarkers, based on subtle changes in DNA structure, proteins, metabolites and other molecules, that will enable scientists to study how the body responds to environmental stress.

The Exposure Biology Program is one of two complementary research programs outlined in the Genes and Environment Initiative, a five-year, NIH-wide effort to identify the genetic and environmental underpinnings of asthma, diabetes, cancer, and other common illnesses. The program will focus on the development of innovative technologies for assessing exposures to chemical and biological agents, dietary intake, physical activity, psychosocial stress, and addictive substances, as well as new methods for quantifying the biological responses to these environmental stressors.

"These new exposure technologies will enable researchers to accelerate their discovery of genetic and environmental risk factors for human disease," said NIEHS Director David A. Schwartz, M.D. "The discoveries made with these new tools will ultimately lead to new strategies for the prevention and treatment of many illnesses."

There is increasing evidence that common human diseases result from a complex interplay between genes and environmental exposures. Population studies designed to investigate the role of gene-environment interactions in human disease have often been hampered by the lack of precise measurement too
'"/>

Contact: John Peterson
peterso4@niehs.nih.gov
919-541-7860
NIH/National Institute of Environmental Health Sciences
18-Oct-2006


Page: 1 2 3

Related biology news :

1. NIEHS researchers identify enzyme critical in DNA replication
2. Two at Yale named outstanding new environmental scientists by NIEHS
3. Columbia University receives $16.9 million NIEHS award to study arsenic in ground water
4. NIEHS researchers link gene variation to coronary heart disease
5. NIEHS Director unveils new strategic plan for environmental health sciences
6. NIEHS awards $37 million to train emergency and hazardous waste workers
7. NIEHS launches website with information for assessing environmental hazards from Hurricane Katrina
8. A role for public and scientists in NIEHS research plan
9. NIEHS to develop new RNAi library to help fight disease
10. US Department of Defense awards $1.6 million for implantable biochip research
11. Nottingham biosciences million pound injection

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIEHS allocates million study environmental causes disease

(Date:5/21/2013)... occur in the body, stem cells in the ... differentiating into mature immune cells that can fight ... deplete these cell populations, potentially leading to the ... Now, a team of researchers led by biologists ... found that, in mouse models, the molecule microRNA-146a ...
(Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
(Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: